Delcath Systems, Inc. (NASDAQ:DCTH) Stock Holdings Lowered by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 55.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 138,242 shares of the company's stock after selling 173,558 shares during the period. Renaissance Technologies LLC owned 0.43% of Delcath Systems worth $1,664,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in shares of Delcath Systems during the fourth quarter worth about $66,000. Barclays PLC acquired a new stake in Delcath Systems during the third quarter worth approximately $104,000. Jane Street Group LLC purchased a new stake in Delcath Systems in the 3rd quarter worth approximately $110,000. Private Advisor Group LLC acquired a new position in Delcath Systems in the 4th quarter valued at $153,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Delcath Systems during the 4th quarter worth $156,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on DCTH shares. HC Wainwright upped their target price on Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, March 7th. Craig Hallum increased their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Delcath Systems presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.75.

Delcath Systems Trading Up 1.0 %

NASDAQ:DCTH traded up $0.12 during mid-day trading on Friday, hitting $12.20. The stock had a trading volume of 91,483 shares, compared to its average volume of 355,491. The company has a 50 day simple moving average of $12.45 and a 200-day simple moving average of $12.47. The stock has a market capitalization of $407.72 million, a price-to-earnings ratio of -9.03 and a beta of 0.85. Delcath Systems, Inc. has a 52 week low of $5.30 and a 52 week high of $16.97.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The business had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.96 million. During the same period last year, the company earned ($0.48) earnings per share. As a group, equities research analysts anticipate that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.